Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Sleep/wake cycle alterations as a cause of neurodegenerative diseases, A Mendelian randomization study

  • Cullell, Natalia|||0000-0001-5118-1014
  • Cárcel-Márquez, Jara|||0000-0002-6949-0699
  • Gallego Fabrega, Cristina|||0000-0003-3229-5512
  • Muiño, Elena|||0000-0001-5839-7328
  • Llucià-Carol, Laia|||0000-0002-7732-0665
  • Lledós, Miquel|||0000-0001-8832-789X
  • Amaut, K.E.U.
  • Krupinski, J.
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
Sleep and/or wake cycle alterations are common in neurodegenerative diseases (ND). Our aim was to determine whether there is a causal relationship between sleep and/or wake cycle patterns and ND (Parkinson's disease (PD) age at onset (AAO), Alzheimer's disease (AD), and amyotrophic lateral sclerosis (ALS)) using two-sample Mendelian Randomization (MR). We selected 12 sleep traits with available Genome-Wide Association Study (GWAS) to evaluate their causal relationship with the ND risk through Inverse-Variance Weighted regression as main analysis. We used as outcome the latest ND GWAS with available summary-statistics: PD-AAO (N = 17,996), AD (N = 21,235) and ALS (N = 40,136). MR results pointed to a causal effect of subjective and objective-measured morning chronotype on later PD-AAO (95%CI:0.33-1.81, p = 8.47×10 and 95%CI:-7.28 to -4.44, p = 5.87×10, respectively). Sleep efficiency was causally associated with a decreased AD risk (95%CI:-20.408 to -0.66, p = 0.04) and daytime sleepiness with an increased ALS risk (95%CI:0.15 to 1.61, p = 0.01). Our study suggests that sleep and/or wake patterns have causal relationship with ND. Given that sleep and/or wake patterns are modifiable risk factors, sleep interventions should be investigated as a potential treatment in PD-AAO, AD and ALS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genome-Wide Association Study of VKORC1 and CYP2C9 on acenocoumarol dose, stroke recurrence and intracranial haemorrhage in Spain

  • Cullell, Natalia|||0000-0001-5118-1014
  • Carrera, Caty|||0000-0002-0804-0969
  • Muiño, Elena|||0000-0001-5839-7328
  • Torres-Aguila, Nuria|||0000-0002-9502-9310
  • Cárcel-Márquez, Jara|||0000-0002-6949-0699
  • González-Sánchez, Jonathan
  • Gallego Fabrega, Cristina|||0000-0003-3229-5512
  • Molina, Jessica
  • Besora, Sarah
  • Sotoca Fernández, Javier|||0000-0003-3400-1434
  • Buongiorno, María-Teresa
  • Jimenez-Conde, Jordi|||0000-0002-2623-6199
  • Giralt Steinhauer, Eva|||0000-0002-7463-0983
  • de Torres-Chacón, Reyes
  • Montaner, Joan|||0000-0003-4845-2279
  • Mancha, Fernando|||0000-0003-0310-0894
  • Cabezas, Juan Antonio
  • Martí-Fàbregas, Joan|||0000-0001-9229-8649
  • Prats Sánchez, Luis Antonio|||0000-0002-3192-4631
  • Camps-Renom, Pol|||0000-0001-6587-6271
  • Purroy, Francisco|||0000-0002-1808-5968
  • Cambray, Serafi
  • Freijo, María del Mar
  • Vives-Bauzá, Cristòfol|||0000-0001-5735-8335
  • Tur, Silvia
  • Font, Maria-Àngels
  • López-Cancio, Elena|||0000-0001-5757-9074
  • Hernández-Pérez, María|||0000-0001-8279-7954
  • Obach, Víctor|||0000-0002-0518-1053
  • Calleja, Ana
  • Arenillas, Juan F.|||0000-0001-7464-6101
  • Rodríguez-Yáñez, Manuel
  • Castillo, José
  • Sobrino, Tomás|||0000-0002-9760-8690
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
  • Krupinski, Jerzy|||0000-0002-5136-8898
Acenocoumarol is an oral anticoagulant with significant interindividual dose variations. Variants in CYP2C9 and VKORC1 have been associated with acenocoumarol maintenance dose. We analysed whether any of the 49 polymorphisms in CYP2C9 and VKORC1 previously associated with acenocoumarol maintenance dose in a Genome-Wide Association study (GWAs) in Dutch population are associated with stroke recurrence, intracranial haemorrhage (ICH) and acenocoumarol maintenance dose in a Spanish population. We performed a GWAs using Human Core Exome-chip (Illumina) in 78 patients stroke patients treated with acenocoumarol for secondary prevention enrolled as part of the prospective investigator-initiated study (IIS) SEDMAN Study. Patients were followed-up a median of 12.8 months. Three and eight patients had recurrent stroke and ICH events, respectively. We found 14 of the 49 published variants associated with acenocoumarol maintenance dose (p < 0.05). Six polymorphisms were associated with stroke recurrence and four variants with ICH (p < 0.05). In conclusion, variants in VKORC1 and CYP2C9 are associated with acenocoumarol maintenance dose, stroke recurrence and ICH in a Spanish cohort. These results highlight the relevance of studying pharmacogenetics associated with efficacy and safety of anticoagulant drugs and justify studies with larger sample size and different ethnic populations.